Indian J Pharm Close
 

Figure 1: Disease-free survival (DFS) of patients receiving 12 weeks of adjuvant or neoadjuvant trastuzumab

Figure 1: Disease-free survival (DFS) of patients receiving 12 weeks of adjuvant or neoadjuvant trastuzumab